Oral PrEP TDF/FTC
Brand name: Truvada
The first ARV developed for PrEP was a daily pill comprised of a two drug combination of tenofovir and emtricitabine (TDF/FTC). It was first approved in 2012, and is now approved for all populations at risk of HIV.
The safety and efficacy of TDF/FTC is well-established. Policy and program decisions are guided by both data from the original randomized clinical trials, as well as newer studies. Demonstration projects, implementation initiatives and evidence from national programs have provided information about challenges and opportunities with oral PrEP delivery, and can help optimize services and identify gaps.
Prevention options that mitigate or eliminate barriers to access are essential. Key populations, including men who have sex with men (MSM), transgender women (TGW), female sex workers (FSW), and adolescent girls and young women (AGYW) need effective options that work and fit into their lives. Each HIV prevention option has unique characteristics, and individuals may prefer a particular PrEP method for any number of reasons.
Ensuring informed choice is key. Oral PrEP is another strategy to help reduce HIV risk. For some people it will be the right one; for others, injectable cabotegravir for PrEP, the dapivirine vaginal ring (the PrEP ring) or another non ARV-based approach will be right. Research and development have created new options; now advocacy is needed to make them viable choices for people who need and want them.
Clinical Trials Evidence
The 2012 US FDA decision and WHO guidance on PrEP demonstration projects were based on data from randomized controlled trials of TDF/FTC and TDF (a generic option). Additional randomized trials since then have added to this evidence base.
Findings from National Introduction and Scale-Up
Visit AVAC’s Global PrEP Tracker for the latest updates to PrEP uptake by country.
For lessons from the field on what works and what innovation is underway check out the resources section from the Prevention Market Manager Project, our report Lessons from Oral PrEP Programs and their Implications for Next Generation Prevention, and the following issue briefs that highlight key findings: